Harmony Biosciences reported strong year-over-year revenue growth for WAKIX® of 20% in the first quarter 2025, building on four consecutive years of profitability, and increased cash and investments to over $600 million on the balance sheet.
WAKIX® net revenue was $184.7 million for Q1 2025, representing 20% growth year-over-year.
Net income grew 19% year-over-year, continuing a trend of four consecutive years of profitability.
Completed recruitment of the Phase 3 registrational trial of ZYN002 in Fragile X Syndrome, with topline data expected in Q3.
On track to initiate Phase 3 registrational trials for next-generation Pitolisant-HD in narcolepsy and IH in Q4 2025.
Harmony Biosciences expects full year 2025 net product revenue to be between $820 million and $860 million, driven by continued commercial success and upcoming pipeline catalysts.
Analyze how earnings announcements historically affect stock price performance